论文部分内容阅读
Background: The Tumor necrosis factor (TNF) is an established therapeutic target for rheumatoid arthritis and other autoimmune diseases.The 5 TNF antagonists available on market now are all protein therapeutics.A major problem limiting development of protein therapeutics is their sensitivity to proteases and delivery challenges.D-Peptides are highly resistant to natural proteases because of the stereospecificity.